Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Liver Neoplasms

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,662 result(s) found for: Liver Neoplasms. Displaying page 15 of 84.
    «« First « Previous 11  12  13  14  15  16  17  18  19  Next» Last»»
    EudraCT Number: 2020-003802-30 Sponsor Protocol Number: OMO-103-01 Start Date*: 2022-09-21
    Sponsor Name:Peptomyc S.L.
    Full Title: A Phase 1/2 Study to evaluate the Safety, Pharmacokinetics, and Anti-Tumour Activity of the Myc Inhibitor OMO-103 administered intravenously in Patients with Advanced Tumours.
    Medical condition: Solid tumours
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-002257-23 Sponsor Protocol Number: 62063 Start Date*: 2009-01-26
    Sponsor Name:European Organization for Research and Treatment of Cancer
    Full Title: A phase III randomized study evaluating surgery of residual disease in patients with metastatic gastro-intestinal stromal tumor responding to Imatinib mesylate.
    Medical condition: Metastatic gastro-intestinal stromal tumor
    Disease: Version SOC Term Classification Code Term Level
    9.1 10062427 Gastrointestinal stromal tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) IT (Prematurely Ended) FR (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-002396-28 Sponsor Protocol Number: IPI-504-06 Start Date*: 2009-02-18
    Sponsor Name:Infinity Pharmaceuticals, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Evaluating the Efficacy and Safety of IPI-504 in Patients with Metastatic and/or Unresectable Gastrointestinal Stromal Tu...
    Medical condition: Metastatic and/or unresectable gastro-intestinal stromal tumors in patients following failure of treatment with at least imatinib and sunitinib.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10062427 Gastrointestinal stromal tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) CZ (Prematurely Ended) ES (Completed) SE (Prematurely Ended) DK (Prematurely Ended) NL (Prematurely Ended) IT (Prematurely Ended) BE (Completed) FR (Completed) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-001834-82 Sponsor Protocol Number: 1613-LCG Start Date*: 2017-10-09
    Sponsor Name:European Organisation for Research and Treatment of Cancer (EORTC)
    Full Title: APPLE trial: Feasibility and activity of AZD9291 (osimertinib) treatment on Positive PLasma T790M in EGFR mutant NSCLC patients
    Medical condition: NSCLC patients
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SI (Completed) ES (Ongoing) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-001929-17 Sponsor Protocol Number: E7080-M000-213 Start Date*: 2017-01-18
    Sponsor Name:EISAI LIMITED
    Full Title: This is an Open-Label, Single-Arm, Multicenter, Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC).
    Medical condition: Anaplastic Thyroid Cancer (ATC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10002240 Anaplastic thyroid cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-005655-16 Sponsor Protocol Number: Regard-CrC_2012 Start Date*: 2013-07-03
    Sponsor Name:Institut Jules Bordet
    Full Title: Regorafenib Assessment in Refractory advanced Colorectal cancer
    Medical condition: Advanced refractory colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2011-001790-41 Sponsor Protocol Number: AB11002 Start Date*: 2013-04-10
    Sponsor Name:AB Science
    Full Title: A prospective, multicenter, randomised, open-label, active-controlled, two-parallel groups, phase 3 study to compare the efficacy and safety of masitinib to sunitinib in patients with gastrointesti...
    Medical condition: Gastrointestinal stromal tumor resistant to imatinib
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062427 Gastrointestinal stromal tumor LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing) ES (Ongoing) NL (Ongoing) DE (Prohibited by CA) BE (Prematurely Ended) AT (Ongoing) GB (GB - no longer in EU/EEA) GR (Prematurely Ended) IT (Suspended by CA) CY (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-003754-61 Sponsor Protocol Number: GS-US-295-0203 Start Date*: 2012-03-08
    Sponsor Name:GILEAD SCIENCE INC.
    Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined with FOLFIRI as Second Line Treatment for Metastatic KRAS Mutant Colorectal Aden...
    Medical condition: Metastatic KRAS Mutant Colorectal Adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052360 Colorectal adenocarcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) ES (Prematurely Ended) DE (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-001725-24 Sponsor Protocol Number: CTKI258AIC02 Start Date*: 2011-10-03
    Sponsor Name:Novartis Pharma Services
    Full Title: DOVIGIST: Phase II trial to evaluate the efficacy and safety of Dovitinib (TKI258) in patients with gastrointestinal stromal tumors refractory and/or intolerant to imatinib
    Medical condition: Unresectable, metastatic or recurrent gastrointestinal stromal tumor (GIST)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062427 Gastrointestinal stromal tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) FI (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-000105-73 Sponsor Protocol Number: OPTIMAL Start Date*: 2019-05-22
    Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI"
    Full Title: Efficacy of metfOrmin in PrevenTIng glucocorticoid-induced diabetes in Melanoma, breAst or Lung cancer patients with brain metastases: the phase II OPTIMAL study
    Medical condition: Patients with melanoma, lung or breast cancer with encephalic metastases.
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027481 Metastatic melanoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10049790 Lung neoplasm NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-005680-25 Sponsor Protocol Number: C/22/2011 Start Date*: 2012-04-24
    Sponsor Name:Imperial College London
    Full Title: A Phase II study to assess the safety and efficacy of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER positive locally advanced or metastatic breast cancer pati...
    Medical condition: Locally advanced or metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070577 Oestrogen receptor positive breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-009277-10 Sponsor Protocol Number: NCT-2008-11-02-1021 Start Date*: 2011-03-24
    Sponsor Name:University Hospital Heidelberg
    Full Title: Neoadjuvant Radiochemotherapy Combined with Panitumumab in Locally Advanced KRAS wild-type Rectal Cancer
    Medical condition: Histologically confirmed, potentially resectable rectal adenocarcinoma staged as uT3/4, N0/1 by endosonography or cT3/4 by MRI of the pelvis with or without local lymph node metastases, but without...
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038052 Rectal carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-000591-42 Sponsor Protocol Number: JX594-IV-HEP021 Start Date*: 2012-09-21
    Sponsor Name:Jennerex, Inc
    Full Title: A Single-Arm, Open-Label Phase 2 Study of JX 594 (Thymidine Kinase-Deactivated Vaccinia Virus plus GM-CSF) Administered by Weekly Intravenous (IV) Infusions in Sorafenib-naïve Patients with Advance...
    Medical condition: Advanced Hepatocellular Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-000773-31 Sponsor Protocol Number: E7050-702 Start Date*: 2011-12-20
    Sponsor Name:Eisai Inc.
    Full Title: An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7050 in Combination with Cetuximab versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head an...
    Medical condition: Squamous Cell Carcinoma of the Head and Neck
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-004301-27 Sponsor Protocol Number: NIBIT-M2 Start Date*: 2012-11-08
    Sponsor Name:FONDAZIONE NIBIT
    Full Title: A randomized, Phase III study of Fotemustine versus the Combination of Fotemustine and Ipilimumab in Patients with Metastatic Melanoma with brain metastasis
    Medical condition: Subjects (men and women) 18 years old presenting with Stage IV melanoma with presence of brain metastasis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025671 Malignant melanoma stage IV PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2022-000525-25 Sponsor Protocol Number: 61186372NSC3004 Start Date*: 2022-09-05
    Sponsor Name:JANSSEN CILAG INTERNATIONAL NV
    Full Title: A Phase 3, Open-label, Randomized Study of Lazertinib with Subcutaneous Amivantamab Administered via Manual Injection Compared with Intravenous Amivantamab or Amivantamab Subcutaneous on Body Deliv...
    Medical condition: EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) PT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-001697-17 Sponsor Protocol Number: R1979-ONC-1504 Start Date*: 2015-12-01
    Sponsor Name:Regeneron Pharmaceuticals, Inc
    Full Title: A Phase 1 Study to Assess Safety and Tolerability of REGN1979, an anti-CD20 x anti- CD3 bispecific monoclonal antibody, and REGN2810, an anti-programmed death-1 monoclonal antibody, in Patients wit...
    Medical condition: B-cell malignancies
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003903 B-cell lymphoma refractory PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003917 B-cell type acute leukaemia PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026945 Mature B-cell type acute leukaemia PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067184 Burkitt's leukaemia PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003890 B precursor type acute leukaemia PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10020267 Hodgkin's disease refractory PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10020266 Hodgkin's disease recurrent PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003902 B-cell lymphoma recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Restarted)
    Trial results: (No results available)
    EudraCT Number: 2019-003108-10 Sponsor Protocol Number: GOING Start Date*: 2020-01-14
    Sponsor Name:Fundació Clinic per a la Recerca Biomèdica
    Full Title: The GOING Study: Regorafenib followed by Nivolumab in patients with Hepatocellular Carcinoma progressing under sorafenib
    Medical condition: Hepatocellular carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073071 Hepatocellular carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-005091-13 Sponsor Protocol Number: SMS Start Date*: 2008-03-06
    Sponsor Name:Guy's & St Thomas' NHS Foundation Trust [...]
    1. Guy's & St Thomas' NHS Foundation Trust
    2. Kings College London (University)
    Full Title: Phase II study of sorafenib in malignant mesothelioma previously treated with platinum-based chemotherapy
    Medical condition: Malignant Mesothelioma
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027407 Mesothelioma malignant PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-004605-29 Sponsor Protocol Number: ML19537 Start Date*: 2006-05-09
    Sponsor Name:ROCHE
    Full Title: A Phase IIIb Study of Tarceva (Erlotinib) in patients with locally advanced, unresectable or metastatic pancreatic cancer
    Medical condition: Locally advanced, unresectable or metastatic pancreatic cancer (adenocarcinoma)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033610 Pancreatic carcinoma metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 11  12  13  14  15  16  17  18  19  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 20 08:52:39 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA